Share on StockTwits

Stock analysts at Robert W. Baird assumed coverage on shares of Theravance Biopharma (NASDAQ:TBPH) in a report issued on Monday, reports. The firm set a “neutral” rating and a $21.00 price target on the stock. Robert W. Baird’s price target points to a potential upside of 7.69% from the stock’s previous close.

Shares of Theravance Biopharma (NASDAQ:TBPH) traded up 1.40% on Monday, hitting $34.87. The stock had a trading volume of 401,742 shares. Theravance Biopharma has a one year low of $14.75 and a one year high of $35.24. The stock’s 50-day moving average is $25.79 and its 200-day moving average is $25.79.

Theravance Biopharma, Inc, is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including bacterial infections, central nervous system (NASDAQ:TBPH)/pain, respiratory disease, and gastrointestinal (GI) motility dysfunction.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.